Streetbeat News

Products Services

CDIO

Cardio Diagnostics announced the publication of results from a Budget Impact Modeling Study for PrecisionCHD, showcasing the potential cost savings and health benefits of their cardiovascular disease early detection technology. The study highlights the effectiveness of PrecisionCHD in reducing healthcare costs while improving patient outcomes through early diagnosis.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:34 pm

MBOT

Microbot Medical announced the results from the first phase of its collaboration with Corewell Health, marking a significant milestone in their partnership. The details of the results were not specified, but the announcement indicates progress in their joint efforts.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:32 pm

SLNO

Soleno Therapeutics' stock is trading higher following the announcement that the FDA granted Breakthrough Therapy Designation for its DCCR extended-release tablets for treating Prader-Willi Syndrome.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:32 pm

IMAX

IMAX and SM Cinema have expanded their partnership by agreeing to install 10 IMAX with Laser systems across the Philippines, more than doubling IMAX's presence in the growing Filipino market. This multi-theatre deal signifies a significant investment in the expansion of high-quality cinematic experiences in the region.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:32 pm

AVGO

MRVL

JPMorgan analyst Harlan Sur highlights Broadcom (AVGO) and Marvell (MRVL) as key beneficiaries of increased AI infrastructure spending by tech giants like Microsoft (MSFT), Alphabet (GOOG/GOOGL), and Meta (META). These companies are investing heavily in GPUs, custom AI compute processors (ASICs), and networking infrastructure, benefiting chip manufacturers. Broadcom's collaboration with Meta and Google on custom silicon chips and Marvell's involvement with Microsoft's next-gen AI processor ASIC indicate significant revenue opportunities for both companies.

Portfolio Pulse from Surbhi Jain

April 29, 2024 | 12:28 pm

LPTV

RDNT

Loop Media, Inc. (LPTV) has been selected by RadNet, Inc. (RDNT) to provide ad sales services, branded channels, and customized signage for RadNet's RadNetTV Channel across its 366 imaging centers. This partnership aims to leverage Loop Media's technology and ad tech stack to deliver programmatic ad sales and personalized entertainment, enhancing RadNetTV's offerings to its viewership of over ten million annually.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:26 pm

COLL

Collegium Pharmaceutical, Inc. (NASDAQ:COLL) has entered into an exclusive agreement with Hikma Pharmaceuticals USA Inc. for the sale of authorized generic versions of Nucynta and Nucynta ER in the U.S. Collegium will manufacture and supply the products, receiving a share of net profits, which will decrease with more generic entrants. This agreement aims to maintain the Nucynta Franchise's value and accessibility.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:22 pm

PRCT

PROCEPT BioRobotics presented outcomes of a post-market survey on Aquablation therapy for men in Japan with lower urinary tract symptoms due to benign prostatic hyperplasia at the JUA. The survey highlights the effectiveness and safety of the therapy.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:21 pm

BMRA

Biomerica, Inc. (BMRA) has entered into a multi-year exclusive distribution agreement with a UAE healthcare conglomerate. The partnership kicks off with an initial order for Biomerica's EZ Detect and Aware products, signaling a significant expansion of the company's global footprint and potential revenue growth.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:20 pm

STOK

Stoke Therapeutics, Inc. (NASDAQ:STOK) announced the appointment of Thomas Leggett as the new Chief Financial Officer, succeeding Stephen Tulipano. Leggett brings over two decades of experience in financial strategy and operations for life science companies. The company highlighted Tulipano's contributions, including leading Stoke's IPO and a $125M public offering. Stoke is advancing its growth phase, focusing on developing STK-001 for Dravet syndrome, transitioning to a late-stage clinical company.

Portfolio Pulse from Benzinga Newsdesk

April 29, 2024 | 12:20 pm